Selecta Biosciences, Inc.
Selecta Biosciences, Inc. (SELB) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
selb · stock forecast · 11 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.67
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.63 | ↓ 5.00% |
1-day model range: $0.62–$0.65. Peak: $0.65 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $0 | -50.0% |
| 2028 | $0 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · SELB · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-08-18 | Needham | Maintains | Buy→Buy |
| 2023-08-18 | Mizuho | Maintains | Buy→Buy |
| 2023-08-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-18 | SVB Leerink | Downgrade ↓ | Outperform→Market Perform |
| 2023-08-17 | SVB Leerink | Downgrade ↓ | Outperform→Market Perform |
| 2023-08-17 | Mizuho | Maintains | Buy→Buy |
| 2023-08-17 | Needham | Maintains | Buy→Buy |
| 2023-08-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-05-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-05-05 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Selecta Biosciences, Inc. (SELB) stock. Of the recent 54 rating actions, 4 were upgrades and 6 were downgrades. 11 analysts currently cover SELB.
Analyst Recommendation Trends
SELB analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 5 to 6 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$49M
↓ 20.9% YoY
Revenue Next Year
$29M
↓ 40.4% YoY
EPS This Year
$-0.23
EPS Next Year
$-0.35
↑ 53.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast SELB EPS of $-0.23 for the current fiscal year, based on estimates from 3 analysts. The SELB revenue forecast is $49M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The SELB stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SELB price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The SELB short-term stock prediction for tomorrow is $0.63 (-5.00%). The SELB stock price prediction for 2027 estimates an average of $0. The SELB stock prediction for 2030 projects a range of $0–$0.
Selecta Biosciences, Inc. trades on NASDAQ under the ticker SELB. The SELB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 91% of covering analysts.
Frequently asked questions
SELB forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month SELB price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.67.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.